ANSWER: B

Rationale:

Tenofovir disoproxil fumarate (TDF) is one of the preferred first-line oral agents for chronic HBV, along with tenofovir alafenamide (TAF) and entecavir. These agents combine potent suppression of HBV reverse transcriptase with the highest resistance barrier of available anti-HBV drugs, making them the standard choice for a treatment-naive patient with normal renal function.

• Option A: Option A is incorrect: lamivudine has a low resistance barrier and selects for the rtM204I/V (YMDD motif) mutation in up to 70% of patients after several years, so it is no longer recommended as initial therapy.
• Option C: Option C is incorrect: adefovir dipivoxil has a low resistance barrier, dose-limiting nephrotoxicity, and slower viral suppression than tenofovir, and has been superseded as first-line therapy.
• Option D: Option D is incorrect: telbivudine also has a low resistance barrier and shares cross-resistance with lamivudine, so it is not a preferred first-line agent.
• Option E: Option E is incorrect: peginterferon alfa-2a is an immune-based finite therapy option, not a nucleos(t)ide analogue; the question specifically asks for a preferred first-line nucleos(t)ide analogue.

ANSWER: D

Rationale:

HCV is a positive-sense ribonucleic acid (RNA) virus that replicates entirely in the cytoplasm and does not integrate into the host genome or form a persistent nuclear reservoir. Because there is no archived template to restart replication, sustained viral suppression with direct-acting antivirals eliminates the virus, and sustained virological response at 12 weeks (SVR12) is durable and equivalent to cure. HBV, by contrast, maintains covalently closed circular DNA (cccDNA) in the nucleus, which allows viral rebound when therapy stops.

• Option A: Option A is incorrect: HCV does not integrate into the host genome at all; genomic integration is not part of its life cycle.
• Option B: Option B is incorrect: HCV is an RNA virus, not a DNA virus, and cure does not depend on host nucleases degrading viral DNA.
• Option C: Option C is incorrect: HCV forms no nuclear reservoir; the absence of such a reservoir, not its depletion, is what permits cure.
• Option E: Option E is incorrect: HCV does not restrict itself to nondividing cells that are slowly replaced; this does not describe the basis of cure.

ANSWER: A

Rationale:

TFV-DP is an acyclic nucleotide analogue that is incorporated into the elongating HBV DNA strand. Because it lacks the 3-prime hydroxyl group required to form the next phosphodiester bond, no further nucleotides can be added, and the chain terminates. This obligate chain-termination mechanism underlies the potent suppression produced by both tenofovir disoproxil fumarate and tenofovir alafenamide.

• Option B: Option B is incorrect: TFV-DP is incorporated into the growing chain rather than acting as an allosteric (non-active-site) inhibitor that alters polymerase conformation.
• Option C: Option C is incorrect: it does not cleave the template strand; HBV reverse transcriptase, not the drug, copies the template.
• Option D: Option D is incorrect: its action is chain termination after incorporation, not sequestration of a host priming protein.
• Option E: Option E is incorrect: tenofovir does not inhibit a protease; HBV maturation is not the target of nucleotide analogues.

ANSWER: C

Rationale:

TAF uses a prodrug strategy that delivers tenofovir to hepatocytes at roughly one-quarter the dose of TDF, producing equivalent HBV suppression while substantially reducing the renal and bone toxicity associated with TDF. This makes TAF the preferred tenofovir formulation in patients with chronic kidney disease or osteoporosis risk, which is directly relevant to this patient with osteopenia and reduced eGFR.

• Option A: Option A is incorrect: TAF and TDF produce comparable virologic suppression; TAF does not increase HBV surface antigen loss, which is primarily an interferon-associated outcome.
• Option B: Option B is incorrect: both tenofovir formulations are dosed once daily, not once weekly.
• Option D: Option D is incorrect: TDF and TAF share an equally high resistance barrier, with no confirmed resistance in treatment-naive patients; TAF is not superior in this respect.
• Option E: Option E is incorrect: TAF improves but does not abolish safety concerns, and monitoring remains appropriate during long-term therapy.

ANSWER: E

Rationale:

SVR12 is defined as undetectable HCV RNA measured 12 weeks after completion of therapy. It is operationally equivalent to cure because fewer than 1% of patients who reach SVR12 experience true virologic relapse. The timing point — 12 weeks after treatment ends, not at the end of treatment — is the defining feature.

• Option A: Option A is incorrect: undetectable RNA at the end of treatment is end-of-treatment response, not SVR12, which requires the 12-week post-treatment time point.
• Option B: Option B is incorrect: ALT normalization reflects reduced hepatic inflammation but does not define virologic cure.
• Option C: Option C is incorrect: a 2-log decline indicates partial response, not the undetectable RNA required for SVR.
• Option D: Option D is incorrect: HCV antibody typically persists for life after exposure and is not used to define cure.

ANSWER: B

Rationale:

Entecavir normally has a very high resistance barrier in treatment-naive patients, but in patients harboring lamivudine-resistance mutations (rtM204I/V plus rtL180M) only one or two additional substitutions are required for high-level entecavir resistance. Entecavir should therefore not be used in patients with known lamivudine or telbivudine resistance; tenofovir-based therapy is preferred in that setting.

• Option A: Option A is incorrect: tenofovir alafenamide retains full activity against lamivudine-resistant HBV and is an appropriate choice here.
• Option C: Option C is incorrect: tenofovir disoproxil fumarate also retains activity against lamivudine-resistant HBV and is in fact a preferred alternative.
• Option D: Option D is incorrect: peginterferon alfa acts by immune modulation and is not affected by nucleos(t)ide resistance mutations; it is not the agent that must be avoided for this reason.
• Option E: Option E is incorrect: a tenofovir-based combination remains effective against lamivudine-resistant HBV and is not the agent specifically contraindicated by these mutations.

ANSWER: A

Rationale:

Sofosbuvir is activated intracellularly to sofosbuvir triphosphate, which is incorporated by the NS5B RNA-dependent RNA polymerase and acts as an obligate chain terminator, halting copying of the HCV genome. Its near-absolute resistance barrier reflects the severe fitness cost of the only relevant resistance substitution (S282T).

• Option B: Option B is incorrect: NS5A is the target of agents such as velpatasvir and ledipasvir, not sofosbuvir; sofosbuvir does not block virion assembly.
• Option C: Option C is incorrect: NS3/4A protease is the target of the "-previr" agents (for example glecaprevir), not sofosbuvir.
• Option D: Option D is incorrect: no approved DAA, including sofosbuvir, acts on the envelope glycoprotein to block entry.
• Option E: Option E is incorrect: CYP3A4 is a host metabolizing enzyme, not the antiviral target of sofosbuvir.

ANSWER: D

Rationale:

Glecaprevir/pibrentasvir is preferred in severe renal impairment, including patients on hemodialysis, because both components are primarily biliary-excreted and neither is renally eliminated. It is approved at standard doses across all genotypes in this population, with SVR12 rates above 98%.

• Option A: Option A is incorrect: sofosbuvir/velpatasvir contains sofosbuvir, which is renally eliminated and not recommended when eGFR is below 30 mL/min/1.73m² without careful consideration.
• Option B: Option B is incorrect: ledipasvir/sofosbuvir likewise contains sofosbuvir and carries the same accumulation concern at very low eGFR.
• Option C: Option C is incorrect: sofosbuvir is never used as monotherapy for HCV and is renally eliminated, making it doubly inappropriate here.
• Option E: Option E is incorrect: this triple regimen also contains sofosbuvir, so it is not the renal-sparing choice in a dialysis patient.

ANSWER: C

Rationale:

HBV maintains a stable pool of cccDNA in the hepatocyte nucleus that serves as a transcriptional template and is not eliminated by nucleos(t)ide analogues. Because this archived template persists, HBV DNA rebounds in the majority of patients if oral therapy is discontinued, so suppressive therapy is generally maintained indefinitely. This contrasts with HCV, which has no nuclear reservoir and can be cured with finite therapy.

• Option A: Option A is incorrect: high-barrier nucleos(t)ide analogues maintain efficacy over many years; loss of effect is not the reason for indefinite therapy.
• Option B: Option B is incorrect: while HBV DNA can integrate, the durable transcriptional template responsible for rebound is episomal cccDNA, not integrated DNA, and rebound is driven by cccDNA persistence rather than integration.
• Option D: Option D is incorrect: although HBV surface antigen loss can permit stopping therapy in selected patients, the underlying reason therapy is otherwise indefinite is cccDNA persistence; surface antigen seroconversion is not universally required.
• Option E: Option E is incorrect: tenofovir has not yielded confirmed resistance in treatment-naive patients, so dose escalation for resistance is not why therapy continues.

ANSWER: E

Rationale:

Combining agents directed at non-overlapping mechanisms means that a single resistance mutation cannot confer escape from the entire regimen, because a virus would need to develop simultaneous resistance to multiple independent targets. This combinational strategy, together with the high potency and high resistance barrier of agents like sofosbuvir, underlies the durable cure achieved by current regimens.

• Option A: Option A is incorrect: the components are dosed for full antiviral activity, not reduced to subtherapeutic levels; dose reduction is not the rationale.
• Option B: Option B is incorrect: these regimens are dosed daily, and combination does not enable weekly dosing.
• Option C: Option C is incorrect: HCV does not form integrated proviral DNA, so this is not a relevant consideration.
• Option D: Option D is incorrect: cure depends on suppressing viral replication, not on increasing renal clearance of the virus, which is not a meaningful mechanism.

ANSWER: A

Rationale:

Although entecavir was initially considered to lack clinically meaningful anti-HIV activity, it has enough activity against HIV reverse transcriptase to select for the methionine-to-valine substitution at codon 184 (M184V) when used without a fully suppressive ARV regimen. To avoid generating HIV drug resistance, an HIV-positive patient receiving entecavir must also be on effective ARV therapy.

• Option B: Option B is incorrect: entecavir retains full activity against HBV regardless of HIV status; the issue is its incidental effect on HIV, not loss of HBV efficacy.
• Option C: Option C is incorrect: the concern is selection of HIV resistance, not drug-induced immune reconstitution worsening HIV.
• Option D: Option D is incorrect: entecavir is not inactivated by ARV protease inhibitors; this is not the mechanism of concern.
• Option E: Option E is incorrect: entecavir does not produce broad elevations in ARV plasma concentrations; the relevant risk is HIV resistance selection.

ANSWER: B

Rationale:

Velpatasvir absorption depends on an acidic gastric environment. PPIs raise gastric pH and reduce velpatasvir exposure, which can compromise efficacy. The management principle is to limit the PPI to an omeprazole-equivalent of no more than 20 mg and take it simultaneously with sofosbuvir/velpatasvir rather than at a separate time of day.

• Option A: Option A is incorrect: PPIs lower, not raise, velpatasvir exposure, so increasing the PPI dose is exactly the wrong response.
• Option C: Option C is incorrect: the interaction is a pH-dependent absorption effect, not CYP3A4 induction of sofosbuvir metabolism.
• Option D: Option D is incorrect: this interaction is not a shared QT-prolongation effect; the concern is reduced absorption.
• Option E: Option E is incorrect: PPIs need not be stopped permanently; they can be used at a limited dose taken together with the regimen.

ANSWER: D

Rationale:

Peginterferon alfa is the only approved HBV therapy capable of producing durable off-treatment responses, including HBeAg seroconversion and, rarely, HBV surface antigen loss. Favorable response predictors — genotype A or B, high baseline ALT, low baseline HBV deoxyribonucleic acid (DNA) — are present in this patient, making finite peginterferon therapy a reasonable option.

• Option A: Option A is incorrect: peginterferon is contraindicated in decompensated cirrhosis, not preferred for it; this patient has no cirrhosis.
• Option B: Option B is incorrect: peginterferon acts through immune modulation and interferon-stimulated gene induction, not chain termination, which is the mechanism of nucleos(t)ide analogues.
• Option C: Option C is incorrect: high baseline ALT is a favorable predictor of response, not a contraindication.
• Option E: Option E is incorrect: peginterferon has substantial adverse effects — flu-like symptoms, cytopenias, neuropsychiatric effects, and thyroid dysfunction — that require monitoring.

ANSWER: C

Rationale:

Glecaprevir/pibrentasvir is approved for 8 weeks in treatment-naive patients without cirrhosis regardless of genotype, making it the shortest approved HCV regimen and a strong choice for a patient who wants minimal treatment duration.

• Option A: Option A is incorrect: sofosbuvir/velpatasvir is given for 12 weeks in treatment-naive patients without cirrhosis, not 8 weeks.
• Option B: Option B is incorrect: ledipasvir/sofosbuvir is a genotype-restricted regimen (genotypes 1, 4, 5, 6) typically given for 8 to 12 weeks and is not the pangenotypic 8-week option described.
• Option D: Option D is incorrect: elbasvir/grazoprevir is a genotype 1 and 4 regimen given for 12 to 16 weeks, not an 8-week pangenotypic course.
• Option E: Option E is incorrect: peginterferon plus ribavirin is an obsolete interferon-based approach requiring far longer treatment with major toxicity, not an 8-week oral regimen.

ANSWER: E

Rationale:

NS3/4A protease inhibitors (the "-previr" agents such as glecaprevir, voxilaprevir, and grazoprevir) are contraindicated in decompensated cirrhosis because protease inhibitor plasma concentrations increase dramatically when hepatic function is impaired, raising toxicity. Sofosbuvir/velpatasvir, with or without ribavirin, is the preferred approach in Child-Pugh B or C disease.

• Option A: Option A is incorrect: the principal contraindication in decompensated cirrhosis is the protease inhibitor class; sofosbuvir (an NS5B nucleotide inhibitor) is actually used in this setting.
• Option B: Option B is incorrect: NS5A inhibitors are not contraindicated by hepatic decompensation and do not require renal dosing as the basis of this restriction.
• Option C: Option C is incorrect: ribavirin is not the agent restricted here, and it is not the only drug affected by hepatic impairment; the protease inhibitors are the contraindicated class.
• Option D: Option D is incorrect: the relevant contraindicated class is the NS3/4A protease inhibitors, not nucleoside analogues, and "hepatic chain termination" is not the reason.

ANSWER: A

Rationale:

All patients starting HCV DAA therapy must be screened for HBsAg and anti-HBc, because clearing HCV removes interferon-driven suppression of HBV and can precipitate HBV reactivation — occasionally causing acute liver failure — in patients with HBV who are not on HBV-active therapy. HBsAg-positive patients require concomitant tenofovir-based HBV therapy; anti-HBc-positive, HBsAg-negative patients require HBV DNA monitoring.

• Option B: Option B is incorrect: routine baseline thyroid testing is relevant to interferon-based therapy, not modern all-oral DAA regimens, and is not the life-threatening omission described.
• Option C: Option C is incorrect: routine G6PD testing is not a required pre-DAA step and is unrelated to the reactivation risk.
• Option D: Option D is incorrect: a pregnancy test in male patients is not applicable, and pregnancy testing is not the screening step that prevents this complication.
• Option E: Option E is incorrect: hepatitis A immunity is not confirmed by PCR and is not the screening that averts HBV reactivation.

ANSWER: C

Rationale:

In patients with advanced fibrosis or cirrhosis, the risk of HCC is reduced but not eliminated by achieving SVR12. These patients require ongoing HCC surveillance by liver ultrasound every 6 months indefinitely, even after virologic cure.

• Option A: Option A is incorrect: SVR12 lowers but does not eliminate HCC risk in established cirrhosis, so surveillance cannot be stopped.
• Option B: Option B is incorrect: residual HCC risk persists regardless of ALT, so surveillance is not contingent on ALT elevation.
• Option D: Option D is incorrect: HCC surveillance uses imaging (ultrasound), not HCV RNA testing, which would detect reinfection rather than cancer.
• Option E: Option E is incorrect: surveillance is driven by the presence of cirrhosis, not by which DAA was used for treatment.

ANSWER: B

Rationale:

Glecaprevir inhibits the hepatic uptake transporters OATP1B1 and OATP1B3, which raises plasma concentrations of statins that depend on these transporters. This effect is significant enough that rosuvastatin is contraindicated with glecaprevir/pibrentasvir, and other statins require dose limitation.

• Option A: Option A is incorrect: the interaction raises statin levels via transporter inhibition rather than inducing statin metabolism and reducing efficacy.
• Option C: Option C is incorrect: the clinically important direction is elevated statin exposure from glecaprevir, not reduced glecaprevir absorption caused by rosuvastatin.
• Option D: Option D is incorrect: this is a transporter-mediated exposure interaction, not a shared QT-prolongation effect.
• Option E: Option E is incorrect: pibrentasvir is primarily biliary-excreted, and rosuvastatin does not drive its renal elimination; the issue is increased statin concentration.

ANSWER: D

Rationale:

An HBsAg-positive patient is at risk of HBV reactivation when HCV is cleared. Such patients should begin HBV-active antiviral therapy (tenofovir disoproxil fumarate or tenofovir alafenamide) simultaneously with or before HCV DAA initiation and continue it for at least 12 weeks after completing HCV treatment, preventing reactivation-related hepatic injury.

• Option A: Option A is incorrect: waiting for jaundice to appear before acting risks acute liver failure; preemptive HBV therapy is required.
• Option B: Option B is incorrect: HCV should be treated, with HBV covered concurrently; HCV therapy is not deferred indefinitely.
• Option C: Option C is incorrect: a single peginterferon dose is not a recognized strategy and does not provide ongoing HBV suppression.
• Option E: Option E is incorrect: HCV should still be treated; the correct approach is concurrent HBV-active therapy, not abandoning HCV treatment.

ANSWER: A

Rationale:

Genotype 3 with cirrhosis is the most difficult contemporary HCV scenario. SVR12 with sofosbuvir/velpatasvir is approximately 88 to 91% in GT3 cirrhotic patients, below the greater-than-95% rate achieved in other populations, and sofosbuvir/velpatasvir/voxilaprevir for 12 weeks is preferred in NS5A-inhibitor-naive GT3 cirrhotic patients where available.

• Option B: Option B is incorrect: GT2 without cirrhosis is among the most treatment-responsive scenarios, not the most difficult.
• Option C: Option C is incorrect: GT1b without cirrhosis responds very well to pangenotypic regimens, with high SVR12 rates.
• Option D: Option D is incorrect: acute GT1a in a young patient is not the recognized hardest-to-cure scenario.
• Option E: Option E is incorrect: GT4 treated for the recommended duration achieves high SVR12 rates and is not the most challenging case.

ANSWER: E

Rationale:

In a triply infected patient, HBV must be covered throughout, typically by a tenofovir-containing ARV backbone that suppresses both HIV and HBV. The most dangerous move is to switch to an HBV-inactive ARV regimen after curing HCV, because withdrawing HBV-active therapy can precipitate catastrophic HBV reactivation and hepatic decompensation. The HBV-active backbone should be continued indefinitely.

• Option A: Option A is incorrect: continuing the tenofovir-based backbone is exactly what protects against HBV reactivation; it is the safe choice, not the risk.
• Option B: Option B is incorrect: surveillance for HCV reinfection is appropriate monitoring and does not provoke HBV reactivation.
• Option C: Option C is incorrect: monitoring hepatic function during therapy is prudent and not a source of reactivation risk.
• Option D: Option D is incorrect: scheduled HCC surveillance is appropriate post-cure care and carries no reactivation risk.

ANSWER: C

Rationale:

NS3/4A protease inhibitors such as glecaprevir are sensitive cytochrome P450 3A4 (CYP3A4) substrates. Ritonavir-boosted atazanavir raises glecaprevir exposure approximately 6-fold, reaching unsafe levels, so this combination is contraindicated. The principle is to review the ARV regimen for DAA interactions before HCV treatment and select a compatible backbone — agents such as dolutegravir, raltegravir, or rilpivirine have minimal interactions with these regimens.

• Option A: Option A is incorrect: boosted atazanavir raises, rather than induces and lowers, glecaprevir exposure; the risk is toxicity, not lost efficacy.
• Option B: Option B is incorrect: the clinically dangerous direction is increased glecaprevir concentration, not reduced atazanavir levels causing HIV breakthrough.
• Option D: Option D is incorrect: the combination is not compatible; it is contraindicated and requires an ARV change.
• Option E: Option E is incorrect: adding ribavirin does not neutralize this pharmacokinetic interaction; the correct response is to avoid the contraindicated combination.